Literature DB >> 2706245

Tryptophan fluorescence as a probe of placental ribonuclease inhibitor binding to angiogenin.

F S Lee1, D S Auld, B L Vallee.   

Abstract

The binding of human placental ribonuclease inhibitor (PRI) to angiogenin, a human protein that induces neovascularization, occurs with a 1:1 stoichiometry and is accompanied by a 50% increase in tryptophan fluorescence. In contrast, the binding of PRI to bovine pancreatic RNase A or to angiogenin oxidized at its single tryptophan residue results in a quenching of fluorescence. These observations suggest that there is a change in the local environment of Trp-89 of angiogenin. Quenching experiments with acrylamide are consistent with the view that Trp-89 is exposed in the native protein and becomes less accessible upon formation of the complex with PRI. Stopped-flow kinetic measurements monitoring the fluorescence enhancement indicate a two-step mechanism for the binding of PRI to angiogenin. The first step involves rapid formation of an enzyme-inhibitor complex, EI, followed by a slower isomerization of EI to a tight enzyme-inhibitor complex, EI*: (Formula: see text). In 0.1 M NaCl at pH 6 and 25 degrees C, the values of K1 and K2 are 0.53 microM and 97 s-1, respectively. The apparent second-order rate constant of association at protein concentrations much less than K1 is approximated by K2/K1 and equals 1.8 X 10(8) M-1 s-1. The corresponding value for the association of PRI with RNase A is only slightly higher, 3.4 X 10(8) M-1 s-1. The effects of pH and sodium chloride concentration on the association rate of PRI with angiogenin suggest the importance of ionizable groups and ionic interactions, respectively, in the association process.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706245     DOI: 10.1021/bi00427a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

Review 1.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

2.  Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.

Authors:  A C Papageorgiou; R Shapiro; K R Acharya
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

3.  The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.

Authors:  Yunxing Li; Sekar Ramachandran; Thuy-Tien T Nguyen; Clint A Stalnecker; Richard A Cerione; Jon W Erickson
Journal:  J Biol Chem       Date:  2019-12-23       Impact factor: 5.157

4.  Rational design and evaluation of mammalian ribonuclease cytotoxins.

Authors:  Jo E Lomax; Chelcie H Eller; Ronald T Raines
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

5.  Modular mutagenesis of human placental ribonuclease inhibitor, a protein with leucine-rich repeats.

Authors:  F S Lee; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 6.  Protein-protein interactions: methods for detection and analysis.

Authors:  E M Phizicky; S Fields
Journal:  Microbiol Rev       Date:  1995-03

7.  A comparison of the predicted and X-ray structures of angiogenin. Implications for further studies of model building of homologous proteins.

Authors:  S C Allen; K R Acharya; K A Palmer; R Shapiro; B L Vallee; H A Scheraga
Journal:  J Protein Chem       Date:  1994-10

8.  Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.

Authors:  C Z Chen; R Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

9.  Selective abolition of pancreatic RNase binding to its inhibitor protein.

Authors:  Kapil Kumar; Michael Brady; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

10.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.